Nanogallium-poly(L-lactide) Composites with Contact Antibacterial Action

In diverse biomedical and other applications of polylactide (PLA), its bacterial contamination and colonization are unwanted. For this reason, this biodegradable polymer is often combined with antibacterial agents or fillers. Here, we present a new solution of this kind. Through the process of simple solvent casting, we developed homogeneous composite films from 28 ± 5 nm oleic-acid-capped gallium nanoparticles (Ga NPs) and poly(L-lactide) and characterized their detailed morphology, crystallinity, aqueous wettability, optical and thermal properties. The addition of Ga NPs decreased the ultraviolet transparency of the films, increased their hydrophobicity, and enhanced the PLA structural ordering during solvent casting. Albeit, above the glass transition, there is an interplay of heterogeneous nucleation and retarded chain mobility through interfacial interactions. The gallium content varied from 0.08 to 2.4 weight %, and films with at least 0.8% Ga inhibited the growth of Pseudomonas aeruginosa PAO1 in contact, while 2.4% Ga enhanced the effect of the films to be bactericidal. This contact action was a result of unwrapping the top film layer under biological conditions and the consequent bacterial contact with the exposed Ga NPs on the surface. All the tested films showed good cytocompatibility with human HaCaT keratinocytes and enabled the adhesion and growth of these skin cells on their surfaces when coated with poly(L-lysine). These properties make the nanogallium-polyl(L-lactide) composite a promising new polymer-based material worthy of further investigation and development for biomedical and pharmaceutical applications.

Biocompatible Gallium Nanodots against Drug-Resistant Bacterial Pneumonia and Liver Abscess

Resistant bacterial infection remains a severe public health threat, and conventional antibiotic drugs work poorly in effectively treating infectious diseases. Here, we developed gallium-based nanodots (Ga NDs), consisting of specific disruption of bacterial iron ability, to treat multidrug-resistant (MDR) Gram-negative bacteria-infected diseases. The Ga NDs significantly suppress the proliferation of two typical MDR bacteria strains (P. aeruginosa and ESBL E. coli) compared with clinically used antibacterial drugs, including penicillin and levofloxacin. Ga NDs could also disrupt the biofilms of these two bacterial strains. In P. aeruginosa infected pneumonia and ESBL E. coli infected acute liver abscess models, the Ga NDs enable substantial inhibition of bacterial growth and reduce the organs' inflammation that resulted in significant improvement of survival. Further, the Ga NDs demonstrated excellent biocompatibility and biosafety characteristics. Together, we believe that our gallium containing nanotherapeutics are expected to be developed into promising alternative therapies to combat drug-resistant bacterial infection.